Biocon, Bristol-Myers in deal for oral insulin drug

MUMBAI Fri Nov 16, 2012 10:49am IST

Related Topics

Stocks

   

MUMBAI (Reuters) - Biocon Ltd, India's top-listed biotechnology company, said it signed an agreement with Bristol-Myers Squibb Co under which the U.S. drugmaker will have the option to get the worldwide license to its oral insulin drug program.

Bristol Myers can choose to assume full responsibility for the development of the drug IN-105, if its mid-stage trial is successful.

Biocon, which has been looking to partner the drug for nearly two years, said it would receive a license fee as well as milestone payments and royalties based on commercial sales of the drug outside India. It will retain the rights to IN-105 in India.

Financial terms of the deal were not available.

Currently, there are no insulin tablets available and patients with diabetes who need insulin -- a naturally occurring protein that controls blood sugar -- must inject it.

Earlier this year, Pfizer scrapped a deal to sell injectable insulin products made by Biocon.

Biocon shares, which rose more than 4 percent in the previous session, were down 0.4 percent on Friday, while the broader market was up 0.3 percent.

(Reporting by Aradhana Aravindan; Editing by G.Ram Mohan)

FILED UNDER:

Health

REUTERS SHOWCASE

Reforms Push

Reforms Push

Modi may order insurance, coal reforms if vote delayed - officials.  Full Article 

Economic Pulse

Economic Pulse

Crank up public spending to revive growth - chief economic adviser.  Full Article 

Sony Cyberattack

Sony Cyberattack

Obama vows U.S. response to North Korea over Sony cyberattack.  Full Article 

Cook Out

Cook Out

Cook out, Morgan in as England ODI captain - reports.  Full Article 

PM's Moves

PM's Moves

Modi moves in to speed up $300 billion stuck projects.  Full Article 

Obama's Message

Obama's Message

Obama's year-end message to Americans: I'm not a lame duck.  Full Article 

India This Week

India This Week

Some of our best photos from this week.   Pictures 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device   Full Coverage